When You Should Give a Struggling Medtech Company a Second Chance: Interview With IONIQ CEO Jared Bauer

Share:

Listens: 0

Medsider Radio: Learn from Proven Medtech and Healthcare Experts

Business


In this episode of Medsider Radio, we caught up with IONIQ Sciences CEO Jared Bauer, who has spent his career turning around struggling medtech companies. He acquired BurnFree Products in 2012, selling it four years later. In 2014, he became CEO of mobile diagnostics system ApolloDx. Shortly after, he became CEO of spin-off company Cibus Biotechnologies, which makes a handheld diagnostic system to test for infectious diseases. In this conversation, Jared explains the two key factors he looks at when determining whether a medical device company is worth trying to turn around, why finding investors who really care about your mission is a strategic benefit, and why he hopes that IONIQ’s devices will one day have a place in your medicine cabinet. Before we jump into the conversation, I wanted to mention a few things:If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content. Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. Since making the premium memberships available, I’ve been pleasantly surprised at how many people have signed up. If you’re interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Jared if you'd rather read it instead.